Dosage and usage of irinotecan hydrochloride liposome injection (Onivyde)

Irinotecan Hydrochloride Liposomal Injection (Onivyde) is an important drug used to treat metastatic pancreatic cancer and is often used in combination with other chemotherapy drugs. Indications include the first-line treatment of adult patients with metastatic pancreatic cancer in combination with oxaliplatin, fluorouracil, and leucovorin, and in combination with fluorouracil and leucovorin in patients whose disease has progressed on gemcitabine. Of note, the drug cannot be used alone to treat metastatic pancreatic cancer.

In terms of usage and dosage, irinotecan hydrochloride liposome injection must follow strict dosage and administration methods. For first-line treatment of patients with metastatic pancreatic cancer, the recommended dose is 50 mg/m² as an intravenous infusion over 90 minutes once every two weeks, regardless of the patient's UGT1A1*28 allele genotype. Irinotecan Hydrochloride Liposomal Injection should be infused before other drugs such as oxaliplatin, fluorouracil, and leucovorin are given. There is currently no recommended dose for patients with serum bilirubin levels above the upper limit of normal.

For those patients with metastatic pancreatic cancer who have disease progression after gemcitabine therapy, the recommended dose of irinotecan hydrochloride liposome injection is70 mg/m² as a 90-minute intravenous infusion every two weeks. If the patient is known to be homozygous for the UGT1A1*28 allele, the recommended initial dose is 50 mg/m². After tolerability assessment, the dose can be increased to 70mg/m² as the tolerated dose for subsequent cycles. Likewise, there are no recommended doses of this type of therapy in patients with serum bilirubin above the upper limit of normal.

Before drug administration, in order to improve the efficacy and reduce side effects, it is recommended to use corticosteroids and antiemetics 30 minutes before each infusion of irinotecan hydrochloride liposome injection This helps reduce discomfort reactions such as nausea and vomiting, making patients feel more comfortable during treatment. Therefore, when clinically applying irinotecan hydrochloride liposome injection, medical staff need to carefully evaluate the patient's condition and conduct reasonable medication management according to the recommended dosage to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.onivyde.com/en-us/hcp